SCHEMBL6922684

SCHEMBL6922684

Clc1ccc(Oc2ccccc2CC2CCNCC2)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 14/20 0.53
HTR2A P28223 10/20 0.53
KCNH2 Q12809 9/20 0.53
SLC6A2 P23975 4/20 0.53
SLC6A3 Q01959 3/20 0.53
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP3A5 P20815 1/20 0.46
CYP2C19 P33261 1/20 0.46
HTR1A P08908 1/20 0.44
PRMT5 O14744 1/20 0.41
WDR77 Q9BQA1 1/20 0.41
GBA1 P04062 1/20 0.41
SOS1 Q07889 1/20 0.40
HTR3A P46098 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6928757 0.86 AR (0.53) SLC6A4HTR2AKCNH2SLC6A2SLC6A3
SCHEMBL6927951 0.85 SLC6A4 (0.63) SLC6A4HTR2AKCNH2SLC6A2SLC6A3
SCHEMBL7526768 0.82 SLC6A4 (0.56) SLC6A4KCNH2SLC6A2SLC6A3CYP2D6
SCHEMBL6922676 0.81 SLC6A4 (0.59) SLC6A4SLC6A2SLC6A3HTR1AGBA1
SCHEMBL6923739 0.80 SLC6A4 (0.50) SLC6A4KCNH2SLC6A2SLC6A3HTR1A
SCHEMBL6925382 0.80 SLC6A4 (0.48) SLC6A4HTR2ASLC6A2SLC6A3CYP2D6
SCHEMBL6926571 0.80 SLC6A4 (0.47) SLC6A4KCNH2SLC6A2SLC6A3CYP2D6
SCHEMBL6925825 0.80 SLC6A4 (0.46) SLC6A4SLC6A2SLC6A3HTR1AGBA1
SCHEMBL6930121 0.80 SLC6A4 (0.44) SLC6A4KCNH2SLC6A2SLC6A3HTR1A
SCHEMBL1405196 0.80 SLC6A4 (0.63) SLC6A4SLC6A2SLC6A3HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6518284-B2 For inhibiting the serotonin and/or noradrenaline reuptake, and are useful as medicaments in disorders in which an increase of levels of those neurotransmitters is necessary FAES, FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS S.A. (ES) 2003-02-11 US claimed
US-20020038031-A1 New 4 - substituted piperidines ORJALES VENERO AURELIO (ES) 2002-03-28 US claimed
EP-1002794-A1 4-[(Aryl)(aryloxy)methyl]piperidine derivatives and their use as serotonin and/or noradrenaline reuptake inhibitors FAES, Fabrica Espanola de Productos Quimicos y Farmaceuticos, S.A. (ES) 2000-05-24 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020038031-A1 New 4 - substituted piperidines ADRA2C, ADRB2, ADRB1 SLC6A4 11/4885HTR2A 36/4885KCNH2 601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.